Track topics on Twitter Track topics that are important to you
The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and adolescents weighing at least 75lbs for the prevention of HIV infection.
The safety and efficacy of the drug were evaluated in the randomised, double-blind multinational DISCOVER trial in 5387 HIV-negative men and transgender women who have sex with men. The trial compared the once-daily Descovy to Truvada.
Original Article: FDA approves second PrEP drug to prevent HIV infectionNEXT ARTICLE
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...